Renalytix Plc (RNLX)
| Market Cap | 105.04M |
| Revenue (ttm) | 3.80M |
| Net Income (ttm) | -42.25M |
| Shares Out | 46.89M |
| EPS (ttm) | -1.22 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 59,731 |
| Open | 2.40 |
| Previous Close | 2.38 |
| Day's Range | 2.12 - 2.40 |
| 52-Week Range | 1.05 - 5.00 |
| Beta | 1.97 |
| Analysts | Strong Buy |
| Price Target | 5.17 (+130.8%) |
| Earnings Date | Jun 29, 2023 |
About RNLX
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical tri... [Read more]
Financial Performance
In 2022, Renalytix's revenue was $2.97 million, an increase of 99.20% compared to the previous year's $1.49 million. Losses were -$45.28 million, 30.4% more than in 2021.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for RNLX stock is "Strong Buy." The 12-month stock price forecast is $5.17, which is an increase of 130.80% from the latest price.
News
Renalytix to Report Third Quarter Fiscal Year 2023 Financial Results on June 9
LONDON and SALT LAKE CITY, June 05, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) will report its third quarter fiscal year 2023 financial results on Friday, June 9, 2023, before m...
Renalytix selects EVERSANA® to expand commercialization of KidneyIntelX for Early-Stage Kidney Disease Prognosis Detection in Patients with Type 2 Diabetes
Model expected to accelerate deployment of KidneyIntelX across key U.S. regions with high rates of diabetic kidney disease and established insurance coverage Model expected to accelerate deployment of...
New Published Real-World Evidence Shows KidneyIntelX™ Utility
Real-World Utility Data Demonstrates KidneyIntelX Optimizes Clinical Management in Early-Stage Chronic Kidney Disease Across Multiple Physician Specialties
Data Supportive of KidneyIntelX Utility in Minorities and Veterans to Be Presented at the National Kidney Foundation Spring Clinical Meeting
In a clinical decision effectiveness study, KidneyIntelX classified more Black vs non-Black patients as high risk for progression of chronic kidney disease, resulting in increased prescription of SGLT...
Renalytix Reports Second Quarter and First Half Fiscal Year 2023 Financial Results
LONDON and SALT LAKE CITY, March 30, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical ...
Renalytix to Report Second Quarter and First Half Fiscal Year 2023 Financial Results on March 30
LONDON and SALT LAKE CITY, March 22, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced that it will report its second quarter and first half fiscal year 2023 financial ...
Renalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
LONDON and SALT LAKE CITY, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will be participating in the upcoming BTIG MedTech, Digital Health, Li...
Renalytix announces a c.$20.3 million private placement
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN OR INTO ANY OTHER...
Renalytix and Partners Awarded $10 Million Horizon Europe Grant to Advance Personalized Medicine in Treating CKD Throughout Europe and the United States
Award for consortium of industry, academic and clinical research leaders to develop personalized drug response tests in chronic kidney disease Award for consortium of industry, academic and clinical r...
Renalytix Reports Financial Results for First Quarter of Fiscal Year 2023
LONDON and SALT LAKE CITY, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical m...
Published Real World Evidence Demonstrates KidneyIntelX™ Improved Clinical Decisions and Outcomes in High-Risk Patients with Early-Stage Diabetic Kidney Disease
Risk scoring by KidneyIntelX resulted in a 4.5-fold increase in new drug prescriptions (for SGLT2 inhibitors) for high risk compared to low risk patients, an observed reduction of HbA1c levels in the ...
Renalytix to Present at Stifel Healthcare Conference
NEW YORK and SALT LAKE CITY, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will participate in the Stifel Healthcare Conference to be held Nove...
Renalytix Reports Full Year Fiscal 2022 Results
LONDON and SALT LAKE CITY, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX), (LSE: RENX) an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical m...
Renalytix to Report Financial Results for Fourth Quarter and Full Year Fiscal 2022 on October 31
NEW YORK and SALT LAKE CITY, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will report its fourth quarter and full year fiscal 2022 financial r...
KidneyIntelX Clinical Utility and Health Economics Validated in Multiple Data Releases at American Society of Nephrology
Four presentations, including first clinical utility findings from multi-year real world evidence results from a major healthcare system underscore value of KidneyIntelX™ platform in improving cost ec...
Renalytix Announces Change to Board of Directors
LONDON and SALT LAKE CITY, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that Ann Berman, non-executive director and chair of the audit and nomination committee...
Renalytix to Present at H.C. Wainwright 24th Annual Global Investment Conference
NEW YORK and SALT LAKE CITY, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the company will participate in a fireside chat at the H.C. Wainwright 24th Ann...
Data Results Published in American Journal of Managed Care demonstrate adoption and clinical utility of KidneyIntelX™ with Primary Care Physicians
98% of 401 Primary Care Physicians confirmed KidneyIntelX has value as a risk decision tool in their adult patients with type 2 diabetes and chronic kidney disease stages 1-3b.
Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2022
LONDON and SALT LAKE CITY, June 30, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical m...
Renalytix to Report Financial Results for Third Quarter Fiscal 2022 on June 30
NEW YORK and SALT LAKE CITY, June 23, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will report its third quarter fiscal 2022 financial results on Thurs...
1,112 Patient Study Demonstrates Clinical Utility and Care Benefits of KidneyIntelX™ Risk Stratification in Stage 1 to 3 Diabetic Kidney Disease Patients
Late-breaking data presented at American Diabetes Association Scientific Sessions® demonstrates increased adherence to care guidelines for physicians using KidneyIntelX risk assessment to improve outc...
KidneyIntelX™ Demonstrates Ability to Assess Risk of Heart Failure Hospitalization and Death in Large International Diabetic Kidney Disease Patient Cohort
Data shared in oral presentation at American Diabetes Association 82 nd Scientific Sessions® and published in Kidney360 highlights importance in early understanding of cardiovascular risk, a leading c...
Renalytix Announces Two Data Presentations on KidneyIntelX™ at American Diabetes Association 82nd Scientific Sessions®
Real-world clinical utility in 1,112 patients tested with KidneyIntelX
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Renalytix Plc - RNLX
NEW YORK , April 23, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Renalytix Plc ("Renalytix" or the "Company") (NASDAQ: RNLX). Such investors are advised to co...
Renalytix plc successful completion of $30.0 million financing package
Director/PDMR Dealing Director/PDMR Dealing